FibroBiologics (FBLG) Cash from Operations (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Cash from Operations of 3291000.0 for Q2 2026, up 17.39% year-over-year from 2803366.26 in Q2 2025, and up 24.59% on a QoQ basis from 4364000.0 in Q1 2026.
FibroBiologics (FBLG) Cash from Operations (2023 - 2026) Analysis & Trends
FibroBiologics has reported Cash from Operations for 4 years, with the latest figure at 3291000.0 in Q2 2026.
- Cash from Operations for Q2 2026 came in at 3291000.0, up 17.39% year-over-year; the trailing twelve-month figure through Jun 2026 was 14790000.0 (up 0.99% YoY), and the FY2025 annual result was 16394000.0, down 37.75% from the prior year.
- Cash from Operations climbed to 3291000.0 in Q2 2026, from 4364000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1139000.0 in Q3 2023 and troughed at 5275000.0 in Q1 2025.
- A 4-year average of 3025071.43 and a median of 3118000.0 in 2024 frame the typical range for Cash from Operations.
- The widest annual swing landed in 2024, when Cash from Operations slumped 128.8%; it then gained 17.39% in 2026.
- A 4-year view of Cash from Operations shows it stood at 1601000.0 in 2023, then tumbled by 91.94% to 3073000.0 in 2024, then declined by 2.93% to 3163000.0 in 2025, then dropped by 4.05% to 3291000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 3291000.0 in Q2 2026, 4364000.0 in Q1 2026, and 3163000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - | -3.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.29 Mn |
| Jun 30, 2026 | -3.29 Mn |
| Mar 31, 2026 | -4.36 Mn |
| Mar 31, 2026 | -4.36 Mn |
| Dec 31, 2025 | -3.16 Mn |
| Dec 31, 2025 | -3.16 Mn |
| Sep 30, 2025 | -3.97 Mn |
| Sep 30, 2025 | -3.97 Mn |
| Jun 30, 2025 | -3.98 Mn |
| Jun 30, 2025 | -3.98 Mn |
| Mar 31, 2025 | -5.28 Mn |
| Mar 31, 2025 | -5.28 Mn |
| Dec 31, 2024 | -3.07 Mn |
| Dec 31, 2024 | -3.07 Mn |
| Sep 30, 2024 | -2.61 Mn |
| Sep 30, 2024 | -2.61 Mn |
| Jun 30, 2024 | -1.95 Mn |
| Jun 30, 2024 | -1.95 Mn |
| Mar 31, 2024 | -4.28 Mn |
| Mar 31, 2024 | -4.28 Mn |